Research briefs · Digital Health · Updated 2026-11-08
USCDI turns provenance into a product requirement
Why health-data products should preserve authorship and source context instead of flattening every imported record.
Thesis
USCDI provenance is not mainly a connectivity or compliance-checkbox problem. USCDI defines a standardized set of health-data classes and elements for interoperable exchange, including a Provenance class with author and author-role elements. turns the quality, lineage, and operational handling of authorship, source context, and exchanged clinical data into part of the product itself. The durable advantage belongs to teams that can show what happened, why it happened, who acted, and how an exception was resolved without erasing the original evidence.
Market context
Editorial analysis: Visible provenance helps a clinician distinguish patient-reported information, locally authored observations, and records received from another organization without implying that one source is automatically superior. This product-design interpretation is not a finding established by the cited source.
Editorial analysis: teams applying this framework may need to consider data lineage, exception handling, and responsibility across the organizations involved.
Evidence
- USCDI defines a standardized set of health-data classes and elements for interoperable exchange, including a Provenance class with author and author-role elements.
- Its Provenance elements make author context part of interoperable data rather than merely an optional back-office audit note.
- ONC published USCDI Version 7 in July 2026. Version 7 includes a Provenance class with Author, Author Role, Author Time Stamp, and Author Organization elements.
- Editorial analysis: a product or implementation should be assessed against its own architecture, operating context, and applicable obligations; the cited source does not validate a particular vendor or deployment.
Competing viewpoints
Editorial analysis: a narrow implementation may reduce cost and complexity, but may leave operational edge cases unresolved.
Editorial analysis: Clinical users may make unsafe inferences when normalized records look equivalent even though their authorship, collection method, or source differs. may be a relevant alternative to evaluate; the appropriate control level depends on context and risk.
Implications
- Architecture must preserve both original evidence and current normalized state; overwriting either one sacrifices auditability or usability.
- Operational metrics should separate transport success from substantive completion, exception age, correction frequency, and customer impact.
- Vendor contracts become product dependencies when authorship, source context, and exchanged clinical data cannot be exported, interpreted, or supported after access ends.
- Governance should assign decision rights across product, compliance, security, and operations before a live exception forces an improvised answer.
Actionable takeaways
- Map the end-to-end journey for authorship, source context, and exchanged clinical data, naming every source system, transformation, decision owner, handoff, and externally visible status.
- Create a field-level data dictionary that records provenance, permitted values, validation logic, retention, and the authority for each critical element.
- Build an exception taxonomy with service targets, escalation ownership, customer communications, and a rule against silently rewriting source evidence.
- Run tabletop tests for malformed input, partner outage, disputed facts, correction, and bulk export; retain the observed results and remediation owners.
- Review the primary source and implementation assumptions on a scheduled cadence, and require legal or regulatory review when scope or claims change.
Limitations and risks
USCDI specifies exchange data, not a complete trust score, reconciliation policy, clinical workflow, or user-interface hierarchy. This analysis interprets one authoritative source as a product-design signal; it is not legal advice and does not resolve fact-specific applicability. The source may be amended, supplemented, delayed, or interpreted through additional guidance. Outcomes also depend on data supplied by counterparties and on organizational controls outside the software. Teams should confirm current requirements, jurisdiction, contracts, technical specifications, and effective dates before relying on any proposed control.
Sources and citations
- United States Core Data for Interoperability (USCDI), Version 7 — Office of the National Coordinator for Health Information Technology, accessed 2026-11-08